Who We are experts in building and successfully managing life sciences businesses in Asia.
Where With more than half the world’s population, Asia’s pharmaceutical market is valued at over US $140 billion. We operate in the fastest growing healthcare markets worldwide, increasing at an annual compounded growth rate of over 10%, more than double the global growth rate for the sector. China, Korea and India are among the top growth contributors globally, and the ASEAN region is expected to be a pharmaceutical market approaching approximately USD 80 billion in value by 2017*. We help companies craft sustainable strategies to establish themselves as leaders in these rapidly expanding markets.
How Many years of successful hands-on experience makes Sidrapex the partner of choice when it comes to crafting successful and sustainable strategies. Sidrapex provides solutions to your problems and helps to optimize your current business strengths, as well as finding the right strategy to capitalize successfully on future strengths.
We bridge the cultural and business gaps between Asia and the rest of the world. There are tremendous opportunities for European, Japanese and US companies in Asia. With the US emerging very slowly from a huge recession, Japan remaining pretty much flat and the prospects in Europe looking very bleak, pharmaceutical and life sciences companies have much to gain from a focus on Asia for growth.
We integrate our clients’ strategic objectives into the structure of our business strategy proposal, which cascades down into the smallest details. We ask questions not only to seek answers but to determine if there are aspects of the strategy that the client hasn’t thought of. This enables Sidrapex to play a second important role to the client, namely that of a sounding board.
Email [email protected] to schedule a free preliminary consultation
*Based on IMS Heath projections